^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    OAS1 (2'-5'-Oligoadenylate synthetase 1)

    i
    Other names: OAS1, 2’-5’-Oligoadenylate Synthetase 1, OIASI, IFI-4, OIAS, 2’-5’-Oligoadenylate Synthetase 1, 40/46kDa, 2’-5’-Oligoadenylate Synthase 1 , (2-5’)Oligo(A) Synthase 1, 2-5A Synthase 1, E18/E16, 2’,5’-Oligoadenylate Synthetase 1 (40-46 KD), 2’-5’-Oligoisoadenylate Synthetase 1, 2’-5’ Oligoadenylate Synthase 1, E16 (2'-5') Oligo A Synthetase, 2’,5’-Oligo A Synthetase 1, 2-5A Synthetase 1, P46/P42 OAS
    Associations

    News

    Trials
    over1year
    Prognostic value and molecular mechanisms of OAS1 in lung adenocarcinoma. (PubMed, BMC Pulm Med)
    OAS1 overexpression influenced survival and immune cell infiltration in patients with LUAD, which might be a potential prognostic gene for LUAD. Moreover, OAS1 contributed to LUAD progression by participating in STAT3-miR-21-OAS1 axis.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • MIR21 (MicroRNA 21) • OAS1 (2'-5'-Oligoadenylate synthetase 1)
    |
    STAT3 expression • STAT3 overexpression • miR-21 expression
    over1year
    Knock down of transforming growth factor beta improves expressions of co-stimulatory molecules, type I interferon-regulated genes, and pro-inflammatory cytokine in PRRSV-inoculated monocyte-derived macrophages. (PubMed, BMC Vet Res)
    These findings demonstrate a strategy of PRRSV for innate immune suppression via an induction of TGFβ expression. These findings also suggest TGFβ as a potential parameter that future PRRSV vaccine and vaccine adjuvant candidates should take into consideration.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • SPP1 (Secreted Phosphoprotein 1) • TGFB1 (Transforming Growth Factor Beta 1) • TLR3 (Toll Like Receptor 3) • IFNA1 (Interferon Alpha 1) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • IFNB1 (Interferon Beta 1) • IRF7 (Interferon Regulatory Factor 7) • OAS1 (2'-5'-Oligoadenylate synthetase 1)
    over2years
    Multi-omics analysis reveals interferon-stimulated gene OAS1 as a prognostic and immunological biomarker in pan-cancer. (PubMed, Front Immunol)
    In addition, cell experiments showed that the knockdown of OAS1 could reduce the invasive ability and increased the apoptosis rate of PAAD cells. These results confirmed that OAS1 could be a prognostic biomarker and therapeutic target for its potential role in CTL dysfunction and macrophage M2 polarization.
    Journal • Pan tumor
    |
    OAS1 (2'-5'-Oligoadenylate synthetase 1)
    over2years
    The EMT-Related Genes GALNT3 and OAS1 are Associated with Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma. (PubMed, Front Biosci (Landmark Ed))
    GALNT3 and OAS1 expression are associated with immune cell infiltration and poor prognosis in LUAD. Their combined expression has high diagnostic value; hence, GALNT3 and OAS1 may be valuable biomarkers for the early detection of LUAD.
    Journal • Immune cell
    |
    OAS1 (2'-5'-Oligoadenylate synthetase 1)
    over2years
    Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types. (PubMed, Front Oncol)
    Meanwhile, silence of OAS1 enhanced cisplatin-induced apoptosis of LUAD and PRAD cells, but weakened cell migration. This pan-cancer study suggests that OAS1can be used as a molecular biomarker for prognosis in pan-cancer and may play an important role in tumor immune response.
    Journal • Tumor mutational burden • Pan tumor
    |
    TMB (Tumor Mutational Burden) • OAS1 (2'-5'-Oligoadenylate synthetase 1)
    |
    cisplatin